Astra Posts Solid 4Q but Lowers Long-Term Outlook

We expect generic competition will weigh on AstraZeneca for many years as it faces one of the longest and most severe patent cliffs

Damien Conover, CFA 27 January, 2011 | 4:59PM
Facebook Twitter LinkedIn

AstraZeneca (AZN) reported fourth-quarter results that slightly exceeded our expectations. However, we don't expect any changes to our 3,298 pence-per share fair value estimate based on the minor outperformance. As we had expected, Astra lowered its long-term revenue outlook for 2014, which now stands at the middle of the range of $28 billion-$34 billion, down from the upper end. We believe the slow uptake of diabetes drug Onglyza along with the U.S. delay on cardiovascular drug Brilinta caused management to lower its guidance, which now closer matches our expectations.

In the quarter, total sales fell 3% operationally versus the prior-year period, slightly better than we had projected. Strong sales from cholesterol-lowering drug Crestor accounted for the majority of the outperformance. While we had already projected robust growth for Crestor of 13% annually over the next three years, we will probably increase our projections based on the drug's recent strength, which we attribute to recently added indications and perceived best-in-class efficacy. The strong Crestor sales help offset generic competition to respiratory drug Pulmicort and oncology drugs Arimidex and Casodex. We expect generic competition will weigh on the company for many years as Astra faces one of the longest and most severe patent cliffs.

We believe Astra has several important new drugs that should help to offset the patent losses. In particular, Brilinta and diabetes drug dapagliflozin are poised to become the next generation of blockbusters.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AstraZeneca PLC8,641.00 GBX-2.31Rating

About Author

Damien Conover, CFA  is an equity analyst and associate director at Morningstar.

© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement